Novo Nordisk expects the Food and Drug Administration to decide by early next year on whether the drugmaker can sell its diabetes injection Ozempic and a related oral formulation as protective of heart health.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,